Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care

Journal Article


Abstract


  • Aims: Guidelines recommend targeted use of antipsychotics in

    delirium for specific symptoms however this approach has not

    been evaluated in randomised trials. To compare the efficacy

    of risperidone relative to placebo in the control of specific

    delirium symptoms in palliative care patients (communication,

    behaviour and/or perceptual disturbances on Nursing

    Delirium Screening Scale) at 72 hours after study commencement.

    Secondary aims were to compare haloperidol and

    placebo; and risperidone and haloperidol.

Authors


  •   Agar, Meera (external author)
  •   Lawlor, Peter (external author)
  •   Quinn, Stephen (external author)
  •   Caplan, Gideon (external author)
  •   Draper, Brian (external author)
  •   Rowett, Debra (external author)
  •   Devilee, Linda (external author)
  •   Fazekas, Belinda (external author)
  •   Sanderson, Christine (external author)
  •   McCaffery, Nicola (external author)
  •   Hardy, Janet (external author)
  •   Le, Brian (external author)
  •   Eckermann, Simon
  •   Hill, Mark (external author)
  •   Currow, David C. (external author)

Publication Date


  • 2015

Citation


  • Agar, M., Lawlor, P., Quinn, S., Caplan, G., Draper, B., Rowett, D., Devilee, L., Fazekas, B., Sanderson, C., McCaffery, N., Hardy, J., Le, B., Eckermann, S., Hill, M. & Currow, D. (2015). Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care. Australasian Journal on Ageing, 34 (Issue Supplement S1), 33-33.

Ro Metadata Url


  • http://ro.uow.edu.au/buspapers/708

Number Of Pages


  • 0

Start Page


  • 33

End Page


  • 33

Volume


  • 34

Issue


  • Issue Supplement S1

Abstract


  • Aims: Guidelines recommend targeted use of antipsychotics in

    delirium for specific symptoms however this approach has not

    been evaluated in randomised trials. To compare the efficacy

    of risperidone relative to placebo in the control of specific

    delirium symptoms in palliative care patients (communication,

    behaviour and/or perceptual disturbances on Nursing

    Delirium Screening Scale) at 72 hours after study commencement.

    Secondary aims were to compare haloperidol and

    placebo; and risperidone and haloperidol.

Authors


  •   Agar, Meera (external author)
  •   Lawlor, Peter (external author)
  •   Quinn, Stephen (external author)
  •   Caplan, Gideon (external author)
  •   Draper, Brian (external author)
  •   Rowett, Debra (external author)
  •   Devilee, Linda (external author)
  •   Fazekas, Belinda (external author)
  •   Sanderson, Christine (external author)
  •   McCaffery, Nicola (external author)
  •   Hardy, Janet (external author)
  •   Le, Brian (external author)
  •   Eckermann, Simon
  •   Hill, Mark (external author)
  •   Currow, David C. (external author)

Publication Date


  • 2015

Citation


  • Agar, M., Lawlor, P., Quinn, S., Caplan, G., Draper, B., Rowett, D., Devilee, L., Fazekas, B., Sanderson, C., McCaffery, N., Hardy, J., Le, B., Eckermann, S., Hill, M. & Currow, D. (2015). Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care. Australasian Journal on Ageing, 34 (Issue Supplement S1), 33-33.

Ro Metadata Url


  • http://ro.uow.edu.au/buspapers/708

Number Of Pages


  • 0

Start Page


  • 33

End Page


  • 33

Volume


  • 34

Issue


  • Issue Supplement S1